Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Conference Correspondent
News, views, and coverage of important topics and discussions from oncology conferences and events.
[widgetkit id="1" name="CC Event Nav"]
Differentiation Syndrome Associated with Enasidenib, a Selective Inhibitor of mIDH2
Read More
Outcomes with Lower-Intensity Therapy in TP53-Mutated AML
Read More
Enasidenib in Mutant-IDH2 Relapsed or Refractory AML: Results of a Phase 1 Dose-Escalation and Expansion Study
Read More
Using a Synthetic Control Arm to Establish Early End Points as Indicators of Overall Survival in Acute Myeloid Leukemia
Read More
Sorafenib plus 5-Azacytidine in Older, Untreated FLT3-ITD–Positive Patients with Acute Myeloid Leukemia
Read More
Achievement of a Negative MRD State After Hypomethylating Agent Therapy in Older Patients with AML to Reduce Risk of Relapse
Read More
Assessment of Molecular Response to Gilteritinib in FLT3 Mutation–Positive Relapsed/Refractory Acute Myeloid Leukemia
Read More
Distinct Patterns of Somatic Mutation Clearance and Association with Clinical Outcome in Patients with AML
Read More
Prognostic Modeling to Predict Outcomes in Older Patients with AML
Read More
A Randomized Phase 2 Study Evaluating Idarubicin and Cytarabine with Clofarabine or Fludarabine in Adults with Newly Diagnosed AML
Read More
13
14
15
16
17
18
19
Page 16 of 25
Results 151 - 160 of 242